The Crohn's Disease Activity Index (CDAI) is currently the gold-standard for measuring disease activity in Crohn's disease (CD) patients.

Crohn's Disease Activity Index items and weighting factors:

Item (daily sum per week)	Weighting factor
Number of liquid or very soft stools	2
Abdominal pain score in one week (rating, 0-3)	5
General well-being (rating, 1-4)	7
Sum of physical findings per week:	20
Arthritis/arthralgia	
Mucocutaneous lesions (e.g. erythema nodosum, aphthous ulcers)	
Iritis/uveitis	
Anal disease (fissure, fistula, *etc*)	
External fistula (enterocutaneous, vesicle, vaginal, *etc*)	
Fever over 37.8°C	
Antidiarrheal use (e.g. diphenoxylate)	30
Abdominal mass (no = 0, equivocal = 2, yes = 5)	10
47 minus hematocrit (males) or 42 minus hematocrit (females)	6
1-x (1-body weight divided by a standard weight)	1

Classification of Disease Severity in Crohn's Disease:

Status	CDAI Score	Description from ACG Guidelines
Remission	< 150	Asymptomatic or without any symptomatic inflammatory sequelae
Mild to moderate	150 to 220	Ambulatory and able to tolerate oral alimentation without manifestations of dehydration, systemic toxicity, abdominal tenderness, painful mass, intestinal obstruction, or > 10% weight loss
Moderate to severe	220 to 450	Failed to respond to treatment for mild to moderate disease, or those with more prominent symptoms of fever, significant weight loss, abdominal pain or tenderness, intermittent nausea or vomiting, or significant anemia
Severe	> 450	Persistent symptoms despite the introduction of conventional corticosteroids or biologic drugs as outpatients, or individuals presenting with high fevers, persistent vomiting, evidence of intestinal obstruction, significant peritoneal signs such as involuntary guarding or rebound tenderness, cachexia, or evidence of an abscess

CDAI Online Calculators are also available.

References:

Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976;70(3):439-444.

Entyvio (Vedolizumab) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Dec. Table 4, Classification of Disease Severity in Crohn’s Disease. Available from: https://www.ncbi.nlm.nih.gov/books/NBK424370/table/T5/

Freeman H. J. (2008). Use of the Crohn's disease activity index in clinical trials of biological agents. World journal of gastroenterology, 14(26), 4127–4130. https://doi.org/10.3748/wjg.14.4127

Swenson A., Womack K., Quinn M., Curhan G. Methods to derive a Crohn's Disease activity index from electronic health records data. Gastroenterology, Volume 164, Issue 4, Supplement, 2023, Pages S26-S27, ISSN 0016-5085. https://doi.org/10.1053/j.gastro.2023.03.056